Two New Biotechs Spin Out From Edinburgh’s Regenerative Medicine Centre
Separate Investments From Syncona and SV Health Investors
Scotland’s investment in regenerative medicine is paying off with two promising start-ups, one targeting liver disease, the other oncology, launching within days of each other.
You may also be interested in...
UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.
A composite endpoint conceals Actemra’s lack of mortality benefit – while life-saving dexamethasone gets EMA endorsement.
The world is waiting for Moderna’s COVID-19 vaccine results, but meanwhile the company is exploring new avenues to secure long-term growth